Royalty Pharma plc (RPRX)
Market Cap | 16.40B |
Revenue (ttm) | 2.32B |
Net Income (ttm) | 184.41M |
Shares Out | 599.59M |
EPS (ttm) | 0.38 |
PE Ratio | 71.97 |
Forward PE | 6.98 |
Dividend | $0.80 (2.93%) |
Ex-Dividend Date | Nov 16, 2023 |
Volume | 1,275 |
Open | 27.07 |
Previous Close | 27.07 |
Day's Range | 26.84 - 27.36 |
52-Week Range | 25.92 - 44.21 |
Beta | 0.42 |
Analysts | Strong Buy |
Price Target | 55.00 (+101.1%) |
Earnings Date | Nov 8, 2023 |
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies an... [Read more]
Financial Performance
In 2022, Royalty Pharma's revenue was $2.24 billion, a decrease of -2.28% compared to the previous year's $2.29 billion. Earnings were $42.83 million, a decrease of -93.09%.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for RPRX stock is "Strong Buy." The 12-month stock price forecast is $55.0, which is an increase of 101.10% from the latest price.
News

Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conferenc...

MedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749)
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: MedinCell (Paris:MEDCL): In a joint press release announcing the financing agreement: Richard Francis, President and CEO of Teva said: “Since lau...

Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
NEW YORK and TEL AVIV, Israel, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYS...

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
TEL AVIV, Israel & NEW YORK--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Royalty Pharma plc (Nasdaq: RPRX), ...

Royalty Pharma Reports Third Quarter 2023 Results
NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2023 and raised full-year 2023 guidance for Adjusted Cash Recei...

Royalty Pharma to pay $1 bln for Roche's SMA drug royalties
Royalty Pharma said on Thursday it has purchased additional royalties on Roche and PTC Therapeutics' oral spinal muscular atrophy (SMA) drug for an upfront payment of $1 billion.

Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billi...

Royalty Pharma Declares Fourth Quarter 2023 Dividend
NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2023 of $0.20 per Class A ordin...

Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S...

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join...

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
• P roceeds to support continued development and commercialization of Endocrine Rare Disease products and general corporate purposes

Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:

Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
NEW YORK and SAINT PREX, Switzerland, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a synthetic royal...

Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
SAINT-PREX, Switzerland & NEW YORK--(BUSINESS WIRE)--Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a synthetic royalty on US net sales ...

Royalty Pharma Reports Second Quarter 2023 Results
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2023 and raised full-year 2023 guidance for Adjusted Cash Recei...

Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023 before the U.S. f...

Royalty Pharma Declares Third Quarter 2023 Dividend
NEW YORK, July 17, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2023 of $0.20 per Class A ordina...

NASDAQ Stocks Hitting New 52-Week Lows: 4 Stocks To Watch
While a very few are just now coming off of all-time highs (Nvidia, among others), some are recently all the way down to new 52-week lows.

Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, ...

Royalty Pharma Reports First Quarter 2023 Results
NEW YORK, May 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2023 and reaffirmed full year 2023 guidance for Adjusted Cash Rec...

Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference
NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 20...

Royalty Pharma Declares Second Quarter 2023 Dividend
NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2023 of $0.20 per Class A ordi...

Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023
NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023 before the U.S. fina...

Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
NEW YORK and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX), the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the life sciences ...

PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
Royalty Pharma has acquired an interest in PureTech's royalty in Karuna Therapeutics' KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds.